Literature DB >> 33409533

Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease.

Edward K Duran1, Aruna D Pradhan2,3.   

Abstract

BACKGROUND: Triglycerides, cholesterol, and their metabolism are linked due to shared packaging and transport within circulating lipoprotein particles. While a case for a causal role of cholesterol-carrying low-density lipoproteins (LDLs) in atherosclerosis is well made, the body of scientific evidence for a causal role of triglyceride-rich lipoproteins (TRLs) is rapidly growing, with multiple lines of evidence (old and new) providing robust support. CONTENT: This review will discuss current perspectives and accumulated evidence that an overabundance of remnant lipoproteins stemming from intravascular remodeling of nascent TRLs-chylomicrons and very low-density lipoproteins (VLDL)-results in a proatherogenic milieu that augments cardiovascular risk. Basic mechanisms of TRL metabolism and clearance will be summarized, assay methods reviewed, and pivotal clinical studies highlighted.
SUMMARY: Remnant lipoproteins are rendered highly atherogenic by their high cholesterol content, altered apolipoprotein composition, and physicochemical properties. The aggregate findings from multiple lines of evidence suggest that TRL remnants play a central role in residual cardiovascular risk. © American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33409533     DOI: 10.1093/clinchem/hvaa296

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

Review 1.  Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.

Authors:  Renato Quispe; Ty Sweeney; Bhavya Varma; Anandita Agarwala; Erin D Michos
Journal:  Curr Atheroscler Rep       Date:  2022-07-27       Impact factor: 5.967

Review 2.  Lipoprotein Assessment in the twenty-first Century.

Authors:  Diego Lucero; Anna Wolska; Zahra Aligabi; Sarah Turecamo; Alan T Remaley
Journal:  Endocrinol Metab Clin North Am       Date:  2022-07-08       Impact factor: 4.748

Review 3.  Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Authors:  Bai-Hui Zhang; Fan Yin; Ya-Nan Qiao; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2022-05-25

Review 4.  New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.

Authors:  Robert S Rosenson; Aleesha Shaik; Wenliang Song
Journal:  J Am Coll Cardiol       Date:  2021-11-02       Impact factor: 27.203

Review 5.  The dawn of a new era of targeted lipid-lowering therapies.

Authors:  Lale Tokgözoğlu; Peter Libby
Journal:  Eur Heart J       Date:  2022-09-07       Impact factor: 35.855

6.  Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation.

Authors:  Yinhua Luo; Shengyu Cui; Changjiang Zhang; Rui Huang; Jinbo Zhao; Ke Su; Dan Luo; Yuanhong Li
Journal:  Int J Gen Med       Date:  2022-02-18

7.  Endothelial Progenitor Cell Levels and Extent of Post-prandial Lipemic Response.

Authors:  Buket Akcan; Asim Örem; Yahya Altinkaynak; Birgül Kural; Cihan Örem; Mehmet Sönmez; Mauro Serafini
Journal:  Front Nutr       Date:  2022-02-14

Review 8.  Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.

Authors:  Hidekatsu Yanai; Hiroki Adachi; Mariko Hakoshima; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 9.  The Interplay of Obesity, Dyslipidemia and Immune Dysfunction: A Brief Overview on Pathophysiology, Animal Models, and Nutritional Modulation.

Authors:  Yongbo She; Rabban Mangat; Sue Tsai; Spencer D Proctor; Caroline Richard
Journal:  Front Nutr       Date:  2022-02-17

10.  Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.

Authors:  Henry N Ginsberg; Chris J Packard; M John Chapman; Jan Borén; Carlos A Aguilar-Salinas; Maurizio Averna; Brian A Ference; Daniel Gaudet; Robert A Hegele; Sander Kersten; Gary F Lewis; Alice H Lichtenstein; Philippe Moulin; Børge G Nordestgaard; Alan T Remaley; Bart Staels; Erik S G Stroes; Marja-Riitta Taskinen; Lale S Tokgözoğlu; Anne Tybjaerg-Hansen; Jane K Stock; Alberico L Catapano
Journal:  Eur Heart J       Date:  2021-12-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.